

HORIZON PHARMACEUTICAL LLC

Form 15-12G

November 04, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

000-25571

(Commission File Number)

HORIZON PHARMACEUTICAL LLC

(Exact name of registrant as specified in its charter)

7 Hamilton Landing, Suite 100

Novato, CA 94949

(415) 408-6200

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Common Stock, \$0.001 par value per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)
Rule 12g-4(a)(2)
Rule 12h-3(b)(1)(i)
Rule
12h-3(b)(1)(ii)
Rule 15d-6

Approximate number of holders of record as of the certification or notice date: 1

Pursuant to the requirements of the Securities Exchange Act of 1934, Horizon Pharmaceutical LLC (f/k/a Raptor Pharmaceutical Corp.) has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: November 4, 2016

HORIZON PHARMACEUTICAL LLC

By: /s/ Paul W. Hoelscher

Name: Paul W. Hoelscher

Title: Executive Vice President, Chief Financial
Officer

[Signature Page to Form 15]